Utama › Kanser Paru-paru Bukan Sel Kecil › Tennessee › Chattanooga
Kajian klinikal Kanser Paru-paru Bukan Sel Kecil di Chattanooga, TN
11 kajian untuk Kanser Paru-paru Bukan Sel Kecil sedang mencari peserta di lokasi dalam dan sekitar Chattanooga (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Mengambil pesertaFasa 3
- Tennessee Oncology, PLLC - Chattanooga Downtown ( Site 0315), Chattanooga
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Mengambil pesertaFasa 3
- Tennessee Oncology - Chattanooga - Downtown, Chattanooga
- Tennessee Oncology - Chattanooga - GHCR Site I, Chattanooga
- Tennessee Oncology - Chattanooga - Memorial Plaza, Chattanooga
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Mengambil pesertaFasa 3
- Tennessee Oncology, PLLC - Chattanooga Downtown, Chattanooga
- Tennessee Oncology, PLLC - Chattanooga Med Park II, Chattanooga
- Tennessee Oncology, PLLC - Chattanooga Memorial, Chattanooga
- dan 1 lagi
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Mengambil pesertaFasa 3
- Tennessee Oncology, PLLC - Chattanooga Downtown, Chattanooga
- Tennessee Oncology, PLLC - Chattanooga - Medical Park II, Chattanooga
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Mengambil pesertaFasa 2
- Tennessee Oncology - Chattanooga, Chattanooga
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Mengambil pesertaFasa 3
- Tennessee Oncology Chattanooga, Chattanooga
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Mengambil pesertaFasa 2
- Research Site, Chattanooga
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Mengambil pesertaFasa 3
- Research Site, Chattanooga
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Mengambil pesertaFasa 3
- Tennessee Oncology Chattanooga, Chattanooga
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Mengambil pesertaFasa 1/2
- Tennessee Oncology, Chattanooga
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Mengambil pesertaFasa 3
- Research Site, Chattanooga
Kajian Kanser Paru-paru Bukan Sel Kecil di bandar lain
- Houston, TX145 kajian
- New York City, NY121 kajian
- Arlington, VA104 kajian
- Nashville, TN97 kajian
- Boston, MA90 kajian
- Los Angeles, CA87 kajian
- St. Louis, MO73 kajian
- Chicago, IL61 kajian
- Baltimore, MD60 kajian
- San Antonio, TX59 kajian
- Columbus, OH57 kajian
- Washington, DC55 kajian
Kajian lain di Chattanooga
- Kanser Metastatik6 kajian
- Myasthenia Gravis6 kajian
- Kanser Ovari5 kajian
- Diabetes4 kajian
- Penyakit Hati Steatotik4 kajian
- Melanoma4 kajian
- Stroke Iskemia4 kajian
- Kanser Kolorektal4 kajian
- Penyakit Buah Pinggang Kronik4 kajian
- Kanser Paru-paru4 kajian
- Kegagalan Ginjal3 kajian
- Aterosklerosis3 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.